Overview

Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer

Status:
Not yet recruiting

Trial end date:
2024-01-05

Target enrollment:

Participant gender:

Summary

This study will evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of AZD5305 when given in combination with new hormonal agents (NHAs) in patients with Metastatic Prostate Cancer

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

AstraZeneca

Treatments:

Abiraterone Acetate